Health & Medicine

STAT+: FDA approves Rocket gene therapy for rare immune disorder

26 sec read0 views0 listens

The FDA has approved Kresladi, a gene therapy developed by Rocket Pharma, for treating severe leukocyte adhesion deficiency type 1 (LAD-1), an ultra-rare disease. This approval highlights advancements in gene therapy and could encourage further investment in rare disease treatments despite the limited market size. Developers should watch for regulatory standards and manufacturing improvements in gene therapies following this approval.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Gaming9 hours ago56 sec read

Everything Coming to Amazon Prime Video in September

Based on the provided content, here are some key points and highlights: Prime Video Library Highlights: Prime Video offers a diverse range of movies and TV shows. Notable titles include "The Silence of the Lambs," "Once Upon a Time... In Hollywood,"...

Ali Nemati

Tech & Gadgets11 hours ago25 sec read

How Toronto is using Clariti's AI to speed up building permit approvals

Toronto has launched a one-year pilot program with Clariti's CivCheck AI software to expedite the city's building permit approval process. This initiative aims to reduce delays caused by incomplete applications, which can add significant costs for de...

Ali Nemati

Legal & Policy14 hours ago30 sec read

The Mail-In Ballot Fight Is Right Back Where It Started, With The Trump Administration Taking Another 'L'

A U.S. district court has granted a temporary restraining order against a new USPS rule requiring states to submit ballot-envelope designs for federal approval, halting implementation of the regulation ahead of the November election. This decision is...

Ali Nemati